RAC1 and colorectal carcinoma: Altogether, our data point to Rac1 as a potential target to overcome therapy resistance for CRC and other types of tumors and suggest that Rac1 inhibitor 1A-116 could represent a good therapeutic agent to overt CRC resistance for 5-FU-based therapies.